- Home
- AGL vs BNTC Comparison
AGL vs BNTC Comparison
Compare AGL & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGL
- BNTC
- Stock Information
- Founded
- AGL 2016
- BNTC 1995
- Country
- AGL United States
- BNTC United States
- Employees
- AGL N/A
- BNTC N/A
- Industry
- AGL Managed Health Care
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- AGL Health Care
- BNTC Health Care
- Exchange
- AGL Nasdaq
- BNTC Nasdaq
- Market Cap
- AGL 443.4M
- BNTC 365.1M
- IPO Year
- AGL 2021
- BNTC N/A
- Fundamental
- Price
- AGL $1.07
- BNTC $13.74
- Analyst Decision
- AGL Hold
- BNTC Strong Buy
- Analyst Count
- AGL 21
- BNTC 5
- Target Price
- AGL $2.97
- BNTC $24.80
- AVG Volume (30 Days)
- AGL 6.3M
- BNTC 39.9K
- Earning Date
- AGL 11-06-2025
- BNTC 11-13-2025
- Dividend Yield
- AGL N/A
- BNTC N/A
- EPS Growth
- AGL N/A
- BNTC N/A
- EPS
- AGL N/A
- BNTC N/A
- Revenue
- AGL $5,901,182,000.00
- BNTC N/A
- Revenue This Year
- AGL N/A
- BNTC N/A
- Revenue Next Year
- AGL $6.37
- BNTC N/A
- P/E Ratio
- AGL N/A
- BNTC N/A
- Revenue Growth
- AGL 11.76
- BNTC N/A
- 52 Week Low
- AGL $0.71
- BNTC $9.09
- 52 Week High
- AGL $6.08
- BNTC $17.15
- Technical
- Relative Strength Index (RSI)
- AGL 40.92
- BNTC 52.04
- Support Level
- AGL $1.11
- BNTC $13.49
- Resistance Level
- AGL $1.18
- BNTC $14.01
- Average True Range (ATR)
- AGL 0.07
- BNTC 0.52
- MACD
- AGL 0.01
- BNTC -0.05
- Stochastic Oscillator
- AGL 25.00
- BNTC 50.77
About AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.